Establishment of pregnant-specific intervals for hemoglobin (Hb) A2, HbF and cut-off points for HbA2 for thalassemia in Chongqing, China

References

1. 1.↵
   1. Taher AT,
   2. Weatherall DJ,
   3. Cappellini MD.

   Thalassaemia. Lancet 2018; 391: 155–167.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Luk’yanenko V,
   2. Droogh M,
   3. Overgaard UM.

   [Thalassaemia and pregnancy]. Ugeskr Laeger 2017; 179: V04160280. [in Danish]

   OpenUrl
3. 3.↵
   1. Li B,
   2. Zhang XZ,
   3. Yin AH,
   4. Zhao QG,
   5. Wu L,
   6. Ma YZ, et al.

   High prevalence of thalassemia in migrant populations in Guangdong Province, China. BMC Public Health 2014; 14: 905.

   OpenUrl
4. 4.↵
   1. He S,
   2. Qin Q,
   3. Yi S,
   4. Wei Y,
   5. Lin L,
   6. Chen S, et al.

   Prevalence and genetic analysis of α- and β-thalassemia in Baise region, a multi-ethnic region in southern China. Gene 2017; 619: 71–75.

   OpenUrl
5. 5.↵
   1. He S,
   2. Li J,
   3. Li DM,
   4. Yi S,
   5. Lu X,
   6. Luo Y, et al.

   Molecular characterization of α- and β-thalassemia in the Yulin region of Southern China. Gene 2018; 655: 61–64.

   OpenUrl
6. 6.↵
   1. Cai W,
   2. Xiong Q,
   3. Tong J,
   4. Dai X,
   5. Zhou B,
   6. Shen S, et al.

   Prevalence and genetic analysis of thalassemia in neonates in Wuhan area: a national megacity in central China. J Matern Fetal Neonatal Med 2021; 34: 2240–2247.

   OpenUrl
7. 7.↵
   1. Thein SL.

   Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis 2018; 70: 54–65.

   OpenUrl
8. 8.↵
   1. Munkongdee T,
   2. Chen P,
   3. Winichagoon P,
   4. Fucharoen S,
   5. Paiboonsukwong K.

   Update in laboratory diagnosis of thalassemia. Front Mol Biosci 2020; 7: 74.

   OpenUrl
9. 9.↵
   1. Needs T,
   2. Gonzalez-Mosquera LF,
   3. Lynch DT.

   Beta thalassemia. StatPearls. [Updated 2021; Accessed 20212 Oct 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531481/
10. 10.↵
    1. Zhang J,
    2. He J,
    3. Mao X,
    4. Zeng X,
    5. Chen H,
    6. Su J, et al.

    Haematological and electrophoretic characterisation of β-thalassaemia in Yunnan province of Southwestern China. BMJ Open 2017; 7: e013367.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Choudhry VP.

    Quality of life in thalassemia major. Indian J Pediatr 2018; 85: 957–958.

    OpenUrl
12. 12.↵
    1. Lai K,
    2. Huang G,
    3. Su L,
    4. He Y.

    The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep 2017; 7: 920.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Han Y,
    2. Dai W,
    3. Liu X,
    4. Li G,
    5. Xu Y,
    6. Ma X, et al.

    [Results of thalassemia screening and genetic diagnosis for 13 738 pregnant women]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2017; 34: 588–591. [in Chinese]

    OpenUrl
14. 14.↵
    1. Han WP,
    2. Huang L,
    3. Li YY,
    4. Han YY,
    5. Li D,
    6. An BQ, et al.

    Reference intervals for HbA2 and HbF and cut-off value of HbA2 for β-thalassemia carrier screening in a Guizhou population of reproductive age. Clin Biochem 2019; 65: 24–28.

    OpenUrl
15. 15.↵
    1. Horowitz LG,
    2. Boyd JC,
    3. ltaie SA,
    4. Ceriotti F,
    5. Garg U,
    6. Horn P, et al.

    EP28-A3c Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved guidelines-Third Edition. CLSI 2010; 28; 1–59.

    OpenUrl
16. 16.↵
    1. Zhao P,
    2. Weng R,
    3. Wu H.

    Molecular spectrum of α- and β-thalassemia mutations in a large ethnic Hakka population in Southern China. Hemoglobin 2018; 42: 117–121.

    OpenUrl
17. 17.↵
    1. He J,
    2. Zeng H,
    3. Zhu L,
    4. Li H,
    5. Shi L,
    6. Hu L.

    Prevalence and spectrum of thalassaemia in Changsha, Hunan province, China: discussion of an innovative screening strategy. J Genet 2017; 96: 327–332.

    OpenUrl
18. 18.↵
    1. Barrett AN,
    2. Saminathan R,
    3. Choolani M.

    Thalassaemia screening and confirmation of carriers in parents. Best Pract Res Clin Obstet Gynaecol 2017; 39: 27–40.

    OpenUrl
19. 19.↵
    1. Hafiza A,
    2. Malisa MY,
    3. Khirotdin RD,
    4. Azlin I,
    5. Azma Z,
    6. Thong MC, et al.

    HbA2 levels in normal, beta-thalassaemia and haemoglobin E carriers by capillary electrophoresis. Malays J Pathol 2012; 34: 161–164.

    OpenUrl
20. 20.↵
    1. Degandt S,
    2. Coens R,
    3. Cauwelier B,
    4. Devos H,
    5. Langlois M,
    6. Emmerechts J.

    Evaluation of four hemoglobin separation analyzers for hemoglobinopathy diagnosis. J Clin Lab Anal 2018; 32: e22224.

    OpenUrl
21. 21.↵
    1. Rodriguez-Capote K,
    2. Higgins TN.

    Incidence of hemoglobinopathies and thalassemias in Northern Alberta. Establishment of reference intervals for HbF and HbA2. Clin Biochem 2015; 48: 698–702.

    OpenUrl
22. 22.↵
    1. Colaco S,
    2. Nadkarni A.

    Borderline HbA2 levels: dilemma in diagnosis of beta-thalassemia carriers. Mutat Res Rev Mutat Res 2021; 788: 108387.

    OpenUrl
23. 23.↵
    1. Tang W,
    2. Zhang C,
    3. Lu F,
    4. Tang J,
    5. Lu Y,
    6. Cui X, et al.

    Spectrum of α-thalassemia and β-thalassemia mutations in the Guilin Region of southern China. Clin Biochem 2015; 48: 1068–1072.

    OpenUrl
24. 24.↵
    1. Traivaree C,
    2. Monsereenusorn C,
    3. Rujkijyanont P,
    4. Prasertsin W,
    5. Boonyawat B.

    Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis. J Blood Med 2018; 9: 35–41.

    OpenUrl
25. 25.↵
    1. Xu C,
    2. Liao B,
    3. Qi Y,
    4. Huangfu Z,
    5. Chen J,
    6. Chen Y.

    Analysis of gene mutation types of α- and β-thalassemia in Fuzhou, Fujian Province in China. Hemoglobin 2018; 42: 143–147.

    OpenUrlCrossRefPubMed